An AI-backed software, the Viz Vascular Suite allows vascular care teams to automatically identify and triage care for suspected pulmonary embolism, aortic dissection, right heart strain and abdominal aortic aneurysm (AAA).
Viz.ai has filed a new 510(k) application with the US Food & Drug Administration (FDA) for the AAA algorithm.
Leveraging AI, the software analyses a host of imaging modalities automatically, including computerised tomography (CT), electrocardiogram (ECG) and more for suspected vascular diseases.
If a suspected pathology is found, the app automatically sends out an alert and shows high-fidelity patient scans on the mobile device of providers.
Clinicians will be able to use the Viz Vascular Suite to coordinate vascular pathology care remotely within the hub and spoke network of a hospital system. It also helps provide synchronous, HIPAA-compliant communication among specialists.
This end-to-end platform for vascular care teams is improved by AI with a view to enabling immediate team activation and facilitating informed, efficient decisions regarding treatments.
Viz.ai CEO Chris Mansi said: “We set out to build a solution where any patient with life-threatening diseases can benefit from AI-powered care coordination with triage and real-time mobile communication. The Viz Vascular Suite will bring the advantages of intelligent care coordination to even more patients and help clinical teams achieve better clinical outcomes.”
“The feedback from our early adopters has been highly positive, and we look forward to expanding access to this solution to our over 1,300 hospital customer base.”